Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human MAP3K8 Antibodies:
anti-Mouse (Murine) MAP3K8 Antibodies:
anti-Rat (Rattus) MAP3K8 Antibodies:
Go to our pre-filtered search.
role of p105 (show CDH13 Antibodies)/Tpl2 signaling in lung homeostasis
rs1042058 GG Crohn's disease -risk polymorphism in TPL2 results in a gain-of-function by increasing TPL2 expression and signalling, thereby amplifying Pattern recognition receptor -initiated outcomes.
MAP3K8 is a direct target of miR (show MLXIP Antibodies)-144-3p, and miR (show MLXIP Antibodies)-144-3p downregulation is a factor in renal cell carcinoma (show MOK Antibodies) progression through potentiation of MAP3K8 expression.
Taken together, these results suggest that Cot kinase might play a critical role in Helicobacter pylori type IV secretion apparatus-dependent early IL-8 (show IL8 Antibodies) secretion and CagA (show S100A8 Antibodies)-dependent late IL-8 (show IL8 Antibodies) secretion as an alternative signaling molecule in the Erk (show EPHB2 Antibodies) pathway.
Studies indicate that Tpl2, a MAP3K, participates in a broad range of cancer-related signaling pathways and induces tumorigenesis and progression of many cancers.
the results of the present study demonstrated that the miR (show MLXIP Antibodies)-509-3p RCC (show XRCC1 Antibodies) suppressor was a significant regulator of the MAP3K8 oncogene (show RAB1A Antibodies), suggesting that it may have a potential therapeutic role in the treatment of renal cell carcinoma (show MOK Antibodies)
findings provide a novel perspective on the role of the IL-33 (show IL33 Antibodies)/ST2 (show SULT2A1 Antibodies)/COT signaling pathway in supporting cancer-associated inflammation in the tumor microenvironment
structurally versatile active site significantly impacts the design of potent, low molecular weight COT kinase inhibitors
TPL2 mediates the phosphorylation of a fraction of nucleophosmin (show NPM1 Antibodies) at threonine 199, an event required for its proteasomal degradation and maintenance of steady-state nucleophosmin (show NPM1 Antibodies) levels.
MAP3K8 and miR-17-5p expression were inversely correlated with treatment response
study to determine whether Tpl2 influences the immune response generated to the extracellular bacterium Citrobacter rodentium, which induces a mixed Th1 (show HAND1 Antibodies) and Th17 response; findings confirm the importance of Tpl2 in driving the development of the proinflammatory Th1 (show HAND1 Antibodies) lineage as well as promoting IL-17A (show IL17A Antibodies) expression and neutrophil recruitment during infection with extracellular bacteria
TPL-2-regulated Ccl24 (show CCL24 Antibodies) in CD11c (show ITGAX Antibodies)+CD11b (show ITGAM Antibodies)+ cells prevents accelerated type-2 mediated immunity to H. polygyrus.
role of p105 (show NEDD9 Antibodies)/Tpl2 signaling in lung homeostasis
this study shows that TPL-2 deficiency leads to severe house duct mite-induced airway allergy, when compared with wild-type mice
The kinase TPL2 activates ERK (show EPHB2 Antibodies) and p38 (show CRK Antibodies) signaling to promote neutrophilic inflammation
TPL2 kinase is a crucial signaling factor in iNKT cells and major mediator of hepatic inflammation.
Taken together this study identified that TPL-2 regulated TH2-mediated inflammation by supporting lipolysis and M2 macrophage activation, preventing TH2 cell expansion and downstream immunopathology and fibrosis.
Map3k8 decreases apoptosis of monocytes and enhances CCR2 (show CCR2 Antibodies) expression on Ly6C(high)CD11c (show ITGAX Antibodies)(low) monocytes of atherosclerotic ApoE (show APOE Antibodies)(-/-) mice fed an high fat diet.
results demonstrate that Tpl2 promotes inflammation in part by constraining FoxP3 (show FOXP3 Antibodies) expression and Treg immunosuppressive functions.
Tpl2 plays a significant role in promoting HCC (show FAM126A Antibodies) development by its pro-inflammatory effect, which suggested that Tpl2 could be a molecular target for HCC (show FAM126A Antibodies) prevention.
This gene is an oncogene that encodes a member of the serine/threonine protein kinase family. The encoded protein localizes to the cytoplasm and can activate both the MAP kinase and JNK kinase pathways. This protein was shown to activate IkappaB kinases, and thus induce the nuclear production of NF-kappaB. This protein was also found to promote the production of TNF-alpha and IL-2 during T lymphocyte activation. This gene may also utilize a downstream in-frame translation start codon, and thus produce an isoform containing a shorter N-terminus. The shorter isoform has been shown to display weaker transforming activity. Alternate splicing results in multiple transcript variants that encode the same protein.
mitogen-activated protein kinase kinase kinase 8
, Ewing sarcoma transformant
, cot (cancer Osaka thyroid) oncogene
, proto-oncogene c-Cot
, proto-oncogene serine/threoine protein kinase
, tumor progression locus 2
, COT proto-oncogene serine/threonine-protein kinase
, cancer Osaka thyroid oncogene
, cancer Osaka thyroid, oncogene
, mitogen activated protein kinase kinase kinase 8
, serine/threonine-protein kinase cot
, serine/threonine kinase (Tpl-2)